AUTHOR=Feng Tingze , Wu Tianzhi , Zhang Yanxia , Zhou Lang , Liu Shanshan , Li Lin , Li Ming , Hu Erqiang , Wang Qianwen , Fu Xiaocong , Zhan Li , Xie Zijing , Xie Wenqin , Huang Xianying , Shang Xuan , Yu Guangchuang 

TITLE=Stemness Analysis Uncovers That The Peroxisome Proliferator-Activated Receptor Signaling Pathway Can Mediate Fatty Acid Homeostasis In Sorafenib-Resistant Hepatocellular Carcinoma Cells

JOURNAL=Frontiers in Oncology

VOLUME=12

YEAR=2022

URL=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2022.912694

DOI=10.3389/fonc.2022.912694

ISSN=2234-943X

ABSTRACT=<p>Hepatocellular carcinoma (HCC) stem cells are regarded as an important part of individualized HCC treatment and sorafenib resistance. However, there is lacking systematic assessment of stem-like indices and associations with a response of sorafenib in HCC. Our study thus aimed to evaluate the status of tumor dedifferentiation for HCC and further identify the regulatory mechanisms under the condition of resistance to sorafenib. Datasets of HCC, including messenger RNAs (mRNAs) expression, somatic mutation, and clinical information were collected. The mRNA expression-based stemness index (mRNAsi), which can represent degrees of dedifferentiation of HCC samples, was calculated to predict drug response of sorafenib therapy and prognosis. Next, unsupervised cluster analysis was conducted to distinguish mRNAsi-based subgroups, and gene/geneset functional enrichment analysis was employed to identify key sorafenib resistance-related pathways. In addition, we analyzed and confirmed the regulation of key genes discovered in this study by combining other omics data. Finally, Luciferase reporter assays were performed to validate their regulation. Our study demonstrated that the stemness index obtained from transcriptomic is a promising biomarker to predict the response of sorafenib therapy and the prognosis in HCC. We revealed the peroxisome proliferator-activated receptor signaling pathway (the PPAR signaling pathway), related to fatty acid biosynthesis, that was a potential sorafenib resistance pathway that had not been reported before. By analyzing the core regulatory genes of the PPAR signaling pathway, we identified four candidate target genes, <italic>retinoid X receptor beta</italic> (<italic>RXRB</italic>), <italic>nuclear receptor subfamily 1 group H member 3</italic> (<italic>NR1H3</italic>), <italic>cytochrome P450 family 8 subfamily B member 1</italic> (<italic>CYP8B1</italic>) and <italic>stearoyl-CoA desaturase</italic> (<italic>SCD</italic>), as a signature to distinguish the response of sorafenib. We proposed and validated that the <italic>RXRB</italic> and <italic>NR1H3</italic> could directly regulate <italic>NR1H3</italic> and <italic>SCD</italic>, respectively. Our results suggest that the combined use of <italic>SCD</italic> inhibitors and sorafenib may be a promising therapeutic approach.</p>